Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells

Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer chemotherapy and pharmacology 2009-05, Vol.63 (6), p.1023-1033
Hauptverfasser: Queiroz, Alexandre F. S, Silva, Rodrigo A, Moura, Raniere M, Dreyfuss, Juliana L, Paredes-Gamero, Edgar J, Souza, Ana C. S, Tersariol, Ivarne L. S, Santos, Elizeu A, Nader, Helena B, Justo, Giselle Z, de Sales, Maurício P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1033
container_issue 6
container_start_page 1023
container_title Cancer chemotherapy and pharmacology
container_volume 63
creator Queiroz, Alexandre F. S
Silva, Rodrigo A
Moura, Raniere M
Dreyfuss, Juliana L
Paredes-Gamero, Edgar J
Souza, Ana C. S
Tersariol, Ivarne L. S
Santos, Elizeu A
Nader, Helena B
Justo, Giselle Z
de Sales, Maurício P
description Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.
doi_str_mv 10.1007/s00280-008-0825-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20601452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20601452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhA3ABCwluKTO28-9YraAgKvVQerYmWXvXJbGLnSzab1-vsqISB06WPb83bzyPsbcIFwhQf04AooECoCmgEWWhnrEVKinyTcnnbAVSqaKsQZ2xVyndA4BCKV-yM2zqBiWIFXNXMfyZdtz5nevcFOKBUz-5vZsOPFhO3Ie9Gfhg8qPnNoaRrwcXPPE9RUc-cdqS82niP8pK8N08kucmHqZdDIOZf5nREe_NMKTX7IWlIZk3p_Oc3X398nP9rbi-ufq-vrwu-rKSU1EqU4teNB1WIExLqoeqUhaNxfzn1log1XS2JqxrzNDGbERJLbSqbEVHG3nOPi19H2L4PZs06dGl4wTkTZiTFlABqlJk8MM_4H2Yo8-zaYFSNTIvKUO4QH0MKUVj9UN0I8WDRtDHEPQSgs4h6GMIWmXNu1PjuRvN5klx2noGPp4ASj0NNpLvXfrLZXesRF1nTixcyiW_NfFpwv-5v19EloKmbcyN724FZGOs8Lgk-QiGNKdu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213483878</pqid></control><display><type>article</type><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</creator><creatorcontrib>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</creatorcontrib><description>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-008-0825-4</identifier><identifier>PMID: 18781302</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - isolation &amp; purification ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Cancer Research ; Caspases - metabolism ; Cell Culture Techniques ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Cliona ; Clione - chemistry ; Flow Cytometry ; Hematologic and hematopoietic diseases ; Humans ; Immunoblotting ; Inhibitory Concentration 50 ; Jurkat Cells ; K562 Cells ; Lectins - isolation &amp; purification ; Lectins - pharmacology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocytes - cytology ; Lymphocytes - drug effects ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology</subject><ispartof>Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1023-1033</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</citedby><cites>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-008-0825-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-008-0825-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21316277$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18781302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Queiroz, Alexandre F. S</creatorcontrib><creatorcontrib>Silva, Rodrigo A</creatorcontrib><creatorcontrib>Moura, Raniere M</creatorcontrib><creatorcontrib>Dreyfuss, Juliana L</creatorcontrib><creatorcontrib>Paredes-Gamero, Edgar J</creatorcontrib><creatorcontrib>Souza, Ana C. S</creatorcontrib><creatorcontrib>Tersariol, Ivarne L. S</creatorcontrib><creatorcontrib>Santos, Elizeu A</creatorcontrib><creatorcontrib>Nader, Helena B</creatorcontrib><creatorcontrib>Justo, Giselle Z</creatorcontrib><creatorcontrib>de Sales, Maurício P</creatorcontrib><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - isolation &amp; purification</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Caspases - metabolism</subject><subject>Cell Culture Techniques</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cliona</subject><subject>Clione - chemistry</subject><subject>Flow Cytometry</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Inhibitory Concentration 50</subject><subject>Jurkat Cells</subject><subject>K562 Cells</subject><subject>Lectins - isolation &amp; purification</subject><subject>Lectins - pharmacology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocytes - cytology</subject><subject>Lymphocytes - drug effects</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9v1DAQxS0EokvhA3ABCwluKTO28-9YraAgKvVQerYmWXvXJbGLnSzab1-vsqISB06WPb83bzyPsbcIFwhQf04AooECoCmgEWWhnrEVKinyTcnnbAVSqaKsQZ2xVyndA4BCKV-yM2zqBiWIFXNXMfyZdtz5nevcFOKBUz-5vZsOPFhO3Ie9Gfhg8qPnNoaRrwcXPPE9RUc-cdqS82niP8pK8N08kucmHqZdDIOZf5nREe_NMKTX7IWlIZk3p_Oc3X398nP9rbi-ufq-vrwu-rKSU1EqU4teNB1WIExLqoeqUhaNxfzn1log1XS2JqxrzNDGbERJLbSqbEVHG3nOPi19H2L4PZs06dGl4wTkTZiTFlABqlJk8MM_4H2Yo8-zaYFSNTIvKUO4QH0MKUVj9UN0I8WDRtDHEPQSgs4h6GMIWmXNu1PjuRvN5klx2noGPp4ASj0NNpLvXfrLZXesRF1nTixcyiW_NfFpwv-5v19EloKmbcyN724FZGOs8Lgk-QiGNKdu</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Queiroz, Alexandre F. S</creator><creator>Silva, Rodrigo A</creator><creator>Moura, Raniere M</creator><creator>Dreyfuss, Juliana L</creator><creator>Paredes-Gamero, Edgar J</creator><creator>Souza, Ana C. S</creator><creator>Tersariol, Ivarne L. S</creator><creator>Santos, Elizeu A</creator><creator>Nader, Helena B</creator><creator>Justo, Giselle Z</creator><creator>de Sales, Maurício P</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>8FD</scope><scope>F1W</scope><scope>FR3</scope><scope>H99</scope><scope>L.F</scope><scope>L.G</scope><scope>P64</scope></search><sort><creationdate>20090501</creationdate><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><author>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - isolation &amp; purification</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Caspases - metabolism</topic><topic>Cell Culture Techniques</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cliona</topic><topic>Clione - chemistry</topic><topic>Flow Cytometry</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Inhibitory Concentration 50</topic><topic>Jurkat Cells</topic><topic>K562 Cells</topic><topic>Lectins - isolation &amp; purification</topic><topic>Lectins - pharmacology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocytes - cytology</topic><topic>Lymphocytes - drug effects</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Queiroz, Alexandre F. S</creatorcontrib><creatorcontrib>Silva, Rodrigo A</creatorcontrib><creatorcontrib>Moura, Raniere M</creatorcontrib><creatorcontrib>Dreyfuss, Juliana L</creatorcontrib><creatorcontrib>Paredes-Gamero, Edgar J</creatorcontrib><creatorcontrib>Souza, Ana C. S</creatorcontrib><creatorcontrib>Tersariol, Ivarne L. S</creatorcontrib><creatorcontrib>Santos, Elizeu A</creatorcontrib><creatorcontrib>Nader, Helena B</creatorcontrib><creatorcontrib>Justo, Giselle Z</creatorcontrib><creatorcontrib>de Sales, Maurício P</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Technology Research Database</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>ASFA: Marine Biotechnology Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Marine Biotechnology Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Queiroz, Alexandre F. S</au><au>Silva, Rodrigo A</au><au>Moura, Raniere M</au><au>Dreyfuss, Juliana L</au><au>Paredes-Gamero, Edgar J</au><au>Souza, Ana C. S</au><au>Tersariol, Ivarne L. S</au><au>Santos, Elizeu A</au><au>Nader, Helena B</au><au>Justo, Giselle Z</au><au>de Sales, Maurício P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>63</volume><issue>6</issue><spage>1023</spage><epage>1033</epage><pages>1023-1033</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18781302</pmid><doi>10.1007/s00280-008-0825-4</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1023-1033
issn 0344-5704
1432-0843
language eng
recordid cdi_proquest_miscellaneous_20601452
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Animals
Antineoplastic agents
Antineoplastic Agents - isolation & purification
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Biological and medical sciences
Cancer Research
Caspases - metabolism
Cell Culture Techniques
Cell Proliferation - drug effects
Cell Survival - drug effects
Cliona
Clione - chemistry
Flow Cytometry
Hematologic and hematopoietic diseases
Humans
Immunoblotting
Inhibitory Concentration 50
Jurkat Cells
K562 Cells
Lectins - isolation & purification
Lectins - pharmacology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphocytes - cytology
Lymphocytes - drug effects
Medical sciences
Medicine
Medicine & Public Health
Oncology
Original Article
Pharmacology. Drug treatments
Pharmacology/Toxicology
title Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A26%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20inhibitory%20activity%20of%20a%20novel%20lectin%20from%20Cliona%20varians%20against%20K562%20human%20erythroleukemia%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Queiroz,%20Alexandre%20F.%20S&rft.date=2009-05-01&rft.volume=63&rft.issue=6&rft.spage=1023&rft.epage=1033&rft.pages=1023-1033&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-008-0825-4&rft_dat=%3Cproquest_cross%3E20601452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213483878&rft_id=info:pmid/18781302&rfr_iscdi=true